N/A N=739 Jump-In: Building Better Bones
Adolescent Development
Primary: Baseline Total Volumetric Bone Density at the Femur 4% Site — 277.25; 270.79 milligrams per cubic centimeter (mg/ccm)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=32 Evaluation of Continuous Saphenous Nerve Block to Supplement a Continuous Sciatic Nerve Block After Ankle Surgery
Orthopedic Surgery of Lower Extremity
Primary: Verbal Pain Scores — 4.2; 5.4 units on a scale
N/A N=2,472 Comparative Effectiveness of Antibiotics for Respiratory Infections
Acute Otitis Media · Acute Sinusitis · Group A Streptococcal Pharyngitis
Primary: Health Related Quality of Life Score — 91.5; 90.2 scores on a scale — p=0.008
N/A N=19 Evaluation of Opticell Ag on Split-Thickness Skin Graft Donor Sites in Adult Subjects
Split-thickness Skin Graft Donor Sites
Primary: Pain — 4.2; 2.5; 1.1 units on a scale
N/A N=183 Cell Phone Messaging to Improve Communication of Critical Laboratory Results to Patients in Rural Uganda
HIV · Tuberculosis
Primary: Participants Initiating Antiretroviral Therapy (ART) Within 28 Days of Abnormal Result — 8; 89 Participants
Phase 2 N=205 Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 70.6; 100.0; 93.9; 80.6 percentage of participants
N/A N=48 Modernization of in vivo-in Vitro Oral Bioperformance Prediction and Assessment
Human Gastrointestinal Physiology Data
Primary: Average Duodenal Fluid pH in Fasted Compared to Fed Participants Administered a Single Dose of Ibuprofen — 5.12; 5.36 pH
Phase 2 N=309 Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap
Leiomyoma
Primary: Percentage of Subjects With Amenorrhea, Defined as no Scheduled or Unscheduled Bleeding/Spotting After the End of the Initial Bleeding Episode Until End of Treatment…
Phase 3 N=632 Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
HIV-1 Infection
Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm — 93.7; 93.9 percentage of participants — p=1.00
Phase 4 N=44 Vitamin D and Coronary Calcification Study
Chronic Kidney Disease · Vitamin D Deficiency · Coronary Calcification
Primary: Coronary Artery (CAC) Score Progression — 74.38; 106.32 Agatston units
N/A N=153 Product Evaluation of a Newly Developed Intermittent Catheter.
Incontinence, Urinary
Primary: Number of Participants Successfully Able to Insert Catheter — 82; 58 Participants
Phase 4 N=70 Improvement of Pain Following Robotic Sacrocolpopexy and Rectocele Repair for Pelvic Organ Prolapse
Pelvic Organ Prolapse
Primary: Visual Analog Scales (VAS) for Pain at 18 Hours Postoperatively — 15.0; 20.5 mm — p=0.52
N/A N=90 PlasmaKinetic (PK) Button Vaporization Electrode for Treatment of Bladder Tumors
Bladder Cancer
Primary: Number of Procedural Complications — 23; 15 complications
Phase 2 N=9 Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study
Epithelial Ovarian Cancer
Primary: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) — 7; 2 participants
Phase 3 N=92 Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia
Friedreich's Ataxia
Primary: Change From Baseline to Week 26 in the Friedreich's Ataxia Rating Scale (FARS)-mNeuro Score — -0.6; -1.0 units on a scale — p=0.5442